HP-004 / Hepius Therapeutics - LARVOL DELTA

A novel antibody-drug conjugate targeting alkaline phosphatases ALPP and ALPPL2 in solid tumors (AACR 2026) - "In parallel, bispecific ADC formats incorporating HP-004 are being explored to further enhance therapeutic index and extend activity to heterogeneous or low-antigen tumors. Collectively, our data support HP-004 as a highly selective ADC candidate with superior internalization, strong preclinical efficacy, and promising potential for translation in solid tumors expressing ALPP/ALPPL2."

ADC • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALPG • ALPP

Human In Use Test of GINPI-HP-004 in Healthy Adults (clinicaltrials.gov) - P=N/A | N=20 | Completed | Sponsor: i+Med S.Coop.

New trial